SHR-A2102 + adebrelimab + cisplatin + carboplatin

A combination regimen consisting of: - **SHR-A2102**, a nectin-4–directed antibody-drug conjugate being developed for solid tumors, including non-small cell lung cancer (NSCLC). SHR-A2102 acts by specifically targeting nectin-4, leading to delivery of a cytotoxic payload to tumor cells expressing this protein. - **Adebrelimab**, a humanized anti–PD-L1 monoclonal antibody, acting as an immune checkpoint inhibitor to enhance antitumor immune response by blocking the interaction between PD-L1 and its receptors. - **Cisplatin** and **carboplatin** are platinum-based chemotherapies that cause DNA crosslinking and subsequent apoptosis in tumor cells. The combination is under investigation in advanced or metastatic non-small cell lung cancer (NSCLC) to evaluate safety, tolerability, dosage, and preliminary efficacy[1][7].